Cardiovascular disease - DiabetesontheNet

Updates from EASD 2017

Don’t Just Screen – Intervene: Protecting the cardiometabolic health of people with severe mental illness

CANVAS and EMPA-REG findings support cardiovascular safety of SGLT2 inhibitors

Breaking news in cardiovascular outcome trials; empagliflozin and stroke; and glycaemic variability in type 1 diabetes

CVD, diabetes complications and care processes in England and Wales

CANVAS trial – cardiovascular benefits, amputations and fractures

Insulin provision therapy associated with higher mortality than insulin sensitising therapy in older people

Vit D or not vit D, that is the question

Studies that changed clinical practice. ACCORD: Action to Control Cardiovascular Risk in Diabetes

PCDS report from the American Diabetes Association’s 77th Scientific Sessions

Cardiovascular disease: The dietary fat debate continues but early tight control is beneficial

Updates from the ADA conference, the NHS RightCare diabetes pathway and more

The SGLT2 inhibitors – where are we now?

Studies that changed clinical practice. UKPDS: United Kingdom Prospective Diabetes Study

Good glycaemic control does improve major CV outcomes: It’s time to pursue national diabetes care targets with vigour

Aspirin for primary prevention of CVD: The controversy remains in diabetes

Conference report: 12th National Conference of the PCDS

Systolic blood pressure in diabetes: Should recommended targets be lowered?